GIOTRIF 30 MG 28 F.C. TABS

Afatinib is a targeted therapy. Afatinib is classified as a Tyrosine Kinase inhibitor; Epidermal Growth Factor Receptor (EGFR) inhibitor. Indications: - Non-small cell lung cancer metastatic EGFR mutation-positive: First-line treatment of metastatic non-small cell lung cancer (NSCLC) in patients whose tumors have nonresistant epidermal growth factor receptor (EGFR) mutations as detected by an approved test. Limitations of use: Safety and efficacy have not been established in patients whose tumors express resistant EGFR mutations. - Non-small cell lung cancer metastatic squamous: Treatment of previously treated metastatic squamous cell NSCLC that has progressed following platinum-based chemotherapy.